Tirzepatide is an innovative dual GIP/GLP-1 receptor agonist. This medication has shown exceptional results in clinical trials for the treatment of type 2 diabetes. By activating both the GIP and GLP-1 receptors, https://ihannahatp102986.mpeblog.com/73161473/tirzepatide-a-promising-novel-agent-for-diabetes